Ann: MDR Record FY24 Performance with Positive EBITDA and NPAT, page-36

https://******.com.au/media/the-cal...ro-twe-sha-oda-mdr-pro-ipg-cxz-?videoId=35991

That was 6 weeks ago and I don’t recall them comparing it to PME.

Comparisons between MedAdvisor and BHP probably silly.

Comparisons within the 86 coys in the HSEC industry group less silly.

Keen to know what is acceptable? SIG? EBO? 4DX?

There’s a grand canyon between some PME and MDR metrics, but they’re both present in the same markets, with access to populations far greater than Australia.

MDR is just scratching the surface with the opportunity available in the US.

Is $250M+ MC too high? I guess the market will decide.